Although no significant differences were observed in minimum SGLs between daily and weekly GH treatment, some participants experienced SGLs <54 mg/dL, which indicates moderate hypoglycemia in ACH grade 2 participants (Table S4) [18]. This evidence concerns the gene GH1 and Hypoglycemia.